This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Syneos Health (SYNH) New Partnership to Enhance Clinical Trials
by Zacks Equity Research
Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.
Why Is Syneos Health (SYNH) Up 4.1% Since Last Earnings Report?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Syneos Health (SYNH) Matches Q4 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Buys Illingworth Research, Expands CRO Base
by Zacks Equity Research
Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.
Syneos Health's (SYNH) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).
Is Syneos Health (SYNH) a Good Value Investor Stock Now?
by Zacks Equity Research
Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.
Here's Why You Should Invest in Syneos Health (SYNH) Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.
New Strong Buy Stocks For November 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
1Life Healthcare (ONEM) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
1Life Healthcare (ONEM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Syneos Health (SYNH) Tops Q3 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health Banks on Essential Therapies Amid Coronavirus Woe
by Zacks Equity Research
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
Syneos Health (SYNH) Down 8.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health-Idorsia Collaborate to Launch Daridorexant in US
by Zacks Equity Research
Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.
Syneos Health (SYNH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 20.83% and 0.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Invitae (NVTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Senseonics Holdings (SENS) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Senseonics Holdings (SENS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Allscripts (MDRX) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
Allscripts (MDRX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Syneos Health (SYNH) Up 9.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down
by Zacks Equity Research
The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.